Close Menu
  • Home
  • Technology
  • Devices
  • Business
  • Science
  • Gadgets
  • Startups
Ayaksız
  • Home
  • Technology

    Lucid and Bolt Plan 25,000 Robotaxis for Europe

    Eylül 18, 2026

    AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

    Eylül 11, 2026

    Apple Expands Device Protection With a $49.99 Family Plan

    Eylül 11, 2026

    Snapdragon 8 Elite Extreme Gen 6 Reportedly Beats MediaTek’s Next Flagship Chipset

    Eylül 11, 2026

    Pinterest CFO Julia Donnelly to Step Down in October

    Ağustos 30, 2026
  • Devices

    Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone

    Kasım 18, 2026

    Router Mode or Access Point Mode? Give Each Network Device a Clear Job

    Kasım 18, 2026

    Scanner Feeder or Glass? Choose According to the Original

    Kasım 13, 2026

    Borderless Printing: Why the Edges of Your Photo Can Disappear

    Kasım 12, 2026

    Camera AE Lock: Recompose a Scene Without Letting Exposure Drift

    Kasım 11, 2026
  • Business

    Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

    Mart 30, 2026

    Motorola Edge 70 Debuts With Snapdragon 7 Gen 4, Ultra-Slim 5.99mm Body

    Kasım 5, 2025

    Samsung Galaxy S26 Series Could See Price Increase Amid Rising Component Costs: Report

    Kasım 4, 2025

    Amazon’s AWS Partners with NBA to Power New AI Basketball Platform

    Ekim 4, 2025

    Billionaire-Backed Bitcoin Firm OranjeBTC to List on Brazil’s B3 Exchange

    Ekim 4, 2025
  • Science

    Double Rainbows: Why the Outer Arc Reverses Its Colors

    Kasım 18, 2026

    Why Ice Floats—and Why Water Behaves Differently Near Freezing

    Kasım 13, 2026

    Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

    Kasım 12, 2026

    A Light-Year Measures Distance: Understanding the Scale Behind Space Headlines

    Kasım 11, 2026

    Why the Sky Is Blue—and Why the Same Atmosphere Produces Red Sunsets

    Kasım 10, 2026
  • Gadgets

    Tripod Center Columns: Extra Height Comes with a Stability Tradeoff

    Kasım 18, 2026

    E Ink Ghosting: Match the Refresh Mode to the Task

    Kasım 13, 2026

    Camera Lens Hoods: Choose the Right Shape and Check the Whole Frame

    Kasım 12, 2026

    Pop Filters and Windscreens: Match Microphone Protection to the Noise

    Kasım 12, 2026

    USB Hub Power: Check Where Your Connected Devices Get Their Energy

    Kasım 11, 2026
  • Startups

    Cache-Control for Startups: No-Cache and No-Store Solve Different Problems

    Kasım 18, 2026

    Dead-Letter Queues: Investigate Before Replaying Failed Messages

    Kasım 13, 2026

    Database Connection Pools: Budget Across Every Application Replica

    Kasım 13, 2026

    Startup Staging Sites: Separate Search Visibility from Access Control

    Kasım 12, 2026

    API Idempotency Keys: Keep a Retry Connected to the Original Operation

    Kasım 11, 2026
Ayaksız
Anasayfa » Blog » Teva and Sanofi’s IBD Drug Achieves Primary Targets in Phase 2 Study
Science

Teva and Sanofi’s IBD Drug Achieves Primary Targets in Phase 2 Study

By ayaksızAralık 17, 2024Yorum yapılmamış2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Israel’s Teva Pharmaceutical Industries and French drugmaker Sanofi announced that their jointly developed drug for treating ulcerative colitis and Crohn’s disease has successfully met its primary goals in a Phase 2b clinical trial.

The drug, named duvakitug, demonstrated strong efficacy across patient subgroups. In the 14-week trial, 36.2% of patients receiving the low dose and 47.8% receiving the high dose achieved clinical remission, compared to 20.45% of those on a placebo. The study, conducted across the U.S., Europe, and Israel, marks the first randomized, placebo-controlled trial to assess a TL1A antibody treatment for Crohn’s disease.

Promising Results and Market Potential

Eric Hughes, Teva’s head of global R&D, said, “The results from the study have exceeded our expectations.” Similarly, Houman Ashrafian, Sanofi’s head of R&D, highlighted duvakitug’s potential as a transformative treatment: “If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options.”

The drug was generally well-tolerated, with no safety signals identified in patients with both ulcerative colitis and Crohn’s disease. Full results of the study will be presented at a scientific forum in 2025.

Next Steps: Phase 3 Development

Teva and Sanofi plan to move forward with Phase 3 development of duvakitug, pending discussions with regulatory authorities. Both companies noted that inflammatory bowel disease (IBD) currently has no cure, underscoring the urgent need for innovative treatments.

Under the partnership agreement, Teva received a $500 million upfront payment from Sanofi and stands to earn up to $1 billion in development and launch milestones. The companies will equally share development costs and split net profits and losses in major markets.

Commercialization Strategy

Sanofi will take the lead on commercialization in North America, Japan, Asia, and other global regions, while Teva will oversee the European, Israeli, and selected markets.

Market Reaction and Investor Sentiment

Following the announcement, U.S.-listed shares of Teva surged 19%, while Sanofi’s shares climbed 4% in early trading. Analysts, including Jefferies’ Glen Santangelo, said the positive trial results will ease investor concerns that had weighed on Teva’s shares after its third-quarter performance.

Both companies remain optimistic that duvakitug could become a blockbuster drug, generating annual sales exceeding $1 billion, and offering new hope to millions of patients suffering from ulcerative colitis and Crohn’s disease worldwide.

 

clinical remission Crohn’s disease drug commercialization duvakitug IBD inflammatory bowel disease pharmaceutical collaboration Phase 2 trial Phase 3 development Sanofi Teva TL1A antibody ulcerative colitis
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
ayaksız
  • Website

Related Posts

Double Rainbows: Why the Outer Arc Reverses Its Colors

Kasım 18, 2026

Why Ice Floats—and Why Water Behaves Differently Near Freezing

Kasım 13, 2026

Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

Kasım 12, 2026
Add A Comment

Comments are closed.

Recent Posts
  • Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone
  • Cache-Control for Startups: No-Cache and No-Store Solve Different Problems
  • Tripod Center Columns: Extra Height Comes with a Stability Tradeoff
  • Double Rainbows: Why the Outer Arc Reverses Its Colors
  • Router Mode or Access Point Mode? Give Each Network Device a Clear Job
Tags
AI AI Chips AI Infrastructure Amazon Android Apple Artificial Intelligence Bitcoin ChatGPT China Cryptocurrency Cybersecurity data centers DeepSeek Donald Trump Electric Vehicles Elon Musk Ether Generative AI Google Huawei India Investment Iphone Meta Microsoft NASA National Security Nvidia OnePlus OpenAI Oppo Realme Samsung semiconductor industry Social media Sony SpaceX Technology Tesla Tether TikTok Vivo WhatsApp Xiaomi
Ayaksız
Instagram
© 2026 Ayaksız.

Type above and press Enter to search. Press Esc to cancel.